Journal Article
J. Nyombayire, Anzala, O., Gazzard, B., Karita, E., Bergin, P., Hayes, P., Kopycinski, J., Omosa-Manyonyi, G., Jackson, A., Bizimana, J., Farah, B., Sayeed, E., Parks, C. L., Inoue, M., Hironaka, T., Hara, H., Shu, T., Matano, T., Dally, L., Barin, B., Park, H., Gilmour, J., Lombardo, A., Excler, J. - L., Fast, P., Laufer, D. S., and Cox, J. H.,
“First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.”,
J Infect Dis, vol. 215, no. 1, pp. 95-104, 2017.
S. Vasan, Hurley, A., Schlesinger, S. J., Hannaman, D., Gardiner, D. F., Dugin, D. P., Boente-Carrera, M., Vittorino, R., Caskey, M., Andersen, J., Huang, Y., Cox, J. H., Tarragona-Fiol, T., Gill, D. K., Cheeseman, H., Clark, L., Dally, L., Smith, C., Schmidt, C., Park, H. H., Kopycinski, J. T., Gilmour, J., Fast, P., Bernard, R., and Ho, D. D.,
“In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.”,
PLoS One, vol. 6, no. 5, p. e19252, 2011.
S. Vasan, Schlesinger, S. J., Chen, Z., Hurley, A., Lombardo, A., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Boente-Carrera, M., Schmidt, C., Fang, Q., Huang, Y., Zaharatos, G. J., Gardiner, D. F., Caskey, M., Seamons, L., Ho, M., Dally, L., Smith, C., Cox, J., Gill, D., Gilmour, J., Keefer, M. C., Fast, P., and Ho, D. D.,
“Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.”,
PLoS One, vol. 5, no. 1, p. e8816, 2010.
S. Vasan, Schlesinger, S. J., Huang, Y., Hurley, A., Lombardo, A., Chen, Z., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Schmidt, C., Song, Y., Seamons, L., Dally, L., Ho, M., Smith, C., Markowitz, M., Cox, J., Gill, D. K., Gilmour, J., Keefer, M. C., Fast, P., and Ho, D. D.,
“Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.”,
PLoS One, vol. 5, no. 1, p. e8617, 2010.
S. Mehendale, van Lunzen, J., Clumeck, N., Rockstroh, J., Vets, E., Johnson, P. R., Anklesaria, P., Barin, B., Boaz, M., Kochhar, S., Lehrman, J., Schmidt, C., Peeters, M., Schwarze-Zander, C., Kabamba, K., Glaunsinger, T., Sahay, S., Thakar, M., Paranjape, R., Gilmour, J., Excler, J. - L., Fast, P., and Heald, A. E.,
“A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.”,
AIDS Res Hum Retroviruses, vol. 24, no. 6, pp. 873-80, 2008.
E. Vardas, Kaleebu, P., Bekker, L. - G., Hoosen, A., Chomba, E., Johnson, P. R., Anklesaria, P., Birungi, J., Barin, B., Boaz, M., Cox, J., Lehrman, J., Stevens, G., Gilmour, J., Tarragona, T., Hayes, P., Lowenbein, S., Kizito, E., Fast, P., Heald, A. E., and Schmidt, C.,
“A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.”,
AIDS Res Hum Retroviruses, vol. 26, no. 8, pp. 933-42, 2010.
M. C. Keefer, Gilmour, J., Hayes, P., Gill, D., Kopycinski, J., Cheeseman, H., Cashin-Cox, M., Naarding, M., Clark, L., Fernandez, N., Bunce, C. A., Hay, C. M., Welsh, S., Komaroff, W., Hachaambwa, L., Tarragona-Fiol, T., Sayeed, E., Zachariah, D., Ackland, J., Loughran, K., Barin, B., Cormier, E., Cox, J. H., Fast, P., and Excler, J. - L.,
“A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.”,
PLoS One, vol. 7, no. 8, p. e41936, 2012.
G. Omosa-Manyonyi, Mpendo, J., Ruzagira, E., Kilembe, W., Chomba, E., Roman, F., Bourguignon, P., Koutsoukos, M., Collard, A., Voss, G., Laufer, D., Stevens, G., Hayes, P., Clark, L., Cormier, E., Dally, L., Barin, B., Ackland, J., Syvertsen, K., Zachariah, D., Anas, K., Sayeed, E., Lombardo, A., Gilmour, J., Cox, J., Fast, P., and Priddy, F.,
“A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.”,
PLoS One, vol. 10, no. 5, p. e0125954, 2015.
F. M. Kibengo, Ruzagira, E., Katende, D., Bwanika, A. N., Bahemuka, U., Haberer, J. E., Bangsberg, D. R., Barin, B., Rooney, J. F., Mark, D., Chetty, P., Fast, P., Kamali, A., and Priddy, F. H.,
“Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.”,
PLoS One, vol. 8, no. 9, p. e74314, 2013.
G. Mutua, Sanders, E., Mugo, P., Anzala, O., Haberer, J. E., Bangsberg, D., Barin, B., Rooney, J. F., Mark, D., Chetty, P., Fast, P., and Priddy, F. H.,
“Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.”,
PLoS One, vol. 7, no. 4, p. e33103, 2012.
W. Jaoko, Nakwagala, F. N., Anzala, O., Manyonyi, G. Omosa, Birungi, J., Nanvubya, A., Bashir, F., Bhatt, K., Ogutu, H., Wakasiaka, S., Matu, L., Waruingi, W., Odada, J., Oyaro, M., Indangasi, J., Ndinya-Achola, J., Konde, C., Mugisha, E., Fast, P., Schmidt, C., Gilmour, J., Tarragona, T., Smith, C., Barin, B., Dally, L., Johnson, B., Muluubya, A., Nielsen, L., Hayes, P., Boaz, M., Hughes, P., Hanke, T., McMichael, A., Bwayo, J., and Kaleebu, P.,
“Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.”,
Vaccine, vol. 26, no. 22, pp. 2788-95, 2008.
W. Jaoko, Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., Adams, E. M., Graham, B. S., Koup, R. A., Bailer, R. T., Smith, C., Dally, L., Farah, B., Anzala, O., Muvunyi, C. M., Bizimana, J., Tarragona-Fiol, T., Bergin, P. J., Hayes, P., Ho, M., Loughran, K., Komaroff, W., Stevens, G., Thomson, H., Boaz, M. J., Cox, J. H., Schmidt, C., Gilmour, J., Nabel, G. J., Fast, P., and Bwayo, J.,
“Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.”,
PLoS One, vol. 5, no. 9, p. e12873, 2010.
B. S. Peters, Jaoko, W., Vardas, E., Panayotakopoulos, G., Fast, P., Schmidt, C., Gilmour, J., Bogoshi, M., Omosa-Manyonyi, G., Dally, L., Klavinskis, L., Farah, B., Tarragona, T., Bart, P. - A., Robinson, A., Pieterse, C., Stevens, W., Thomas, R., Barin, B., McMichael, A. J., McIntyre, J. A., Pantaleo, G., Hanke, T., and Bwayo, J.,
“Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.”,
Vaccine, vol. 25, no. 11, pp. 2120-7, 2007.
]